comparemela.com

Latest Breaking News On - தீவிரம் சோதனை சோதனை - Page 1 : comparemela.com

SQI Diagnostics Inc Announces Grant of Stock Options

SQI Diagnostics and McMaster University Announce $900,000 Collaborative Research and Development Grant

SQI Diagnostics and McMaster University Announce $900,000 Collaborative Research and Development Grant
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

SQI Diagnostics and McMaster University Announce $900,000 Collaborative Research and Development Grant

SQI Diagnostics and McMaster University Announce $900,000 Collaborative Research and Development Grant
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

SQI Diagnostics Submits RALI-Dx; IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization

with Confirmed COVID-19 Illness TORONTO, April 1, 2021 /PRNewswire/ - SQI Diagnostics Inc. (the Company or SQI ) (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, announces that it has submitted its fully completed clinical and analytical data package to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of its RALI-Dx ™ IL-6 Severity Triage Test. The submission was completed on March 31, 2021. The FDA will review the application under its pre-emergency use authorization (PEUA) process before a definitive EUA review. Subject to the acceptance of an EUA, the RALI-Dx

SQI Diagnostics Receives $2 3 Million in Funds from Shareholder Exercise of Securities

Share this article Company Continues to Improve Gross Cash Position to Execute Business Plan TORONTO, March 8, 2021 /PRNewswire/ - SQI Diagnostics Inc. (the Company or SQI ) (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, announces that 9,775,972 common share purchase warrants (the Warrants ) and 1,500,000 stock options (the Options ) have been exercised at exercise prices between $0.09 and $0.30 per common shares since January 1, 2021, resulting in gross proceeds of approximately $2.3 million to the Company (the Funding ). The Options were exercised by a director of the Company and the Warrants were exercised by non-insiders of the Company.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.